Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis
Diego Curtò, Federica Tomatis, Sara Gastoldi, Miriam Galbusera, Marina Noris, Federico Raimondi, Ferdinando Luca Lorini, Anna Falanga, Marina Marchetti, Giuseppe Remuzzi, Piero Ruggenenti, Diego Curtò, Federica Tomatis, Sara Gastoldi, Miriam Galbusera, Marina Noris, Federico Raimondi, Ferdinando Luca Lorini, Anna Falanga, Marina Marchetti, Giuseppe Remuzzi, Piero Ruggenenti
Abstract
Passive antibody therapy has been used to treat outbreaks of viral disease, including the ongoing pandemic of severe respiratory acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) or COVID-19. However, the real benefits of the procedure are unclear. We infused a concentrated solution of neutralizing anti-SARS-CoV-2 antibodies obtained from a convalescent donor with a single session of double filtration plasmapheresis (DFPP) into a 56-year-old woman with long history of unremitting, severe COVID-19. She was unable to establish an adequate antiviral immune response because of previous chemotherapy, including the infusion of the anti-CD20 monoclonal antibody rituximab, administered to treat a diffuse large B-cell lymphoma. The disease promptly recovered despite evidence of no endogenous anti-SARS-CoV-2 antibody production. The observation that passive antibody therapy might prove particularly effective in immunodepressed COVID-19 patients requires evaluation in prospective randomized controlled trial.
Keywords: COVID-19; case report; coagulation biomarkers; convalescent antibodies; double filtration plasmapheresis; hypercoagulability; immunosuppression; rituximab.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Copyright © 2021 Curtò, Tomatis, Gastoldi, Galbusera, Noris, Raimondi, Lorini, Falanga, Marchetti, Remuzzi and Ruggenenti.
Figures
References
- Pau AK, Aberg J, Baker J, Belperio PS, Coopersmith C, Crew P, et al. . Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. Ann Intern Med (2021) 174:93–5. 10.7326/M20-6448
- Available at: (Accessed on April, 21, 2021).
- Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment? Ann Intern Med (2006) 145:599–609. 10.7326/0003-4819-145-8-200610170-00139
- Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, et al. . Use of Convalescent Plasma Therapy in SARS Patients in Hong Kong. Eur J Clin Microbiol Infect Dis (2005) 24:44–6. 10.1007/s10096-004-1271-9
- Zhou B, Zhong N, Guan Y. Treatment With Convalescent Plasma for Influenza A (H5N1) Infection. N Engl J Med (2007) 357:1450–1. 10.1056/NEJMc070359
- Hung IF, To KK, Lee C-K, Lee K-L, Chan K, Yan W-W, et al. . Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection. Clin Infect Dis (2011) 52:447–56. 10.1093/cid/ciq106
- van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. . Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med (2016) 374:33–42. 10.1056/NEJMoa1511812
- Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, et al. . A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med (2021) 384:619–29. 10.1056/NEJMoa2031304
- Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. PLACID Trial Collaborators. Convalescent Plasma in the Management of Moderate Covid-19 in Adults in India: Open Label Phase II Multicentre Randomised Controlled Trial (PLACID Trial). BMJ (2020) 371:m3939. 10.1136/bmj.m3939
- Mineshima M, Akiba T. Double Filtration Plasmapheresis in Critical Care. Ther Apher (2002) 6:180–3. 10.1046/j.1526-0968.2002.00428.x
- Hung IFN, To KKW, Lee C-K, Lee K-L, Yan W-W, Chan K, et al. . Hyperimmune IV Immunoglobulin Treatment: A Multicenter Double-Blind Randomized Controlled Trial for Patients With Severe 2009 Influenza A(H1N1) Infection. Chest (2013) 144:464–73. 10.1378/chest.12-2907
- Podestà MA, Gennarini A, Portalupi V, Rota S, Alessio MG, Remuzzi G, et al. . Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients With Severe Membranous Nephropathy: Preliminary Findings With Double Filtration Plasmapheresis and Ofatumumab. Nephron (2020) 144:30–5. 10.1159/000501858
- Galbusera M, Noris M, Gastoldi S, Bresin E, Mele C, Breno M, et al. . An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. Am J Kidney Dis (2019) 74:56–72. 10.1053/j.ajkd.2018.11.012
- Ministero della Salute . Consiglio Superiore Di Sanità. Available at: .
- Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. . Human Neutralizing Antibodies Elicited by SARS-CoV-2 Infection. Nature (2020) 584:115–9. 10.1038/s41586-020-2380-z
- von Heymann C, Keller MK, Spies C, Schuster M, Meinck K, Sander M, et al. . Activity of Clotting Factors in Fresh-Frozen Plasma During Storage at 4 Degrees C Over 6 Days. Transfusion (2009) 49:913–20. 10.1111/j.1537-2995.2008.02063.x
- Freedman M, Rock G. Analysis of the Products of Cryoprecipitation: RiCoF Is Deficient in Cryosupernatant Plasma. Transfus Apher Sci (2010) 43:179–82. 10.1016/j.transci.2010.07.004
- Youssef I, Abuelela S, Hamza W. FV, FVIII and Fibrinogen Activity in Fresh Frozen Plasma, Frozen Plasma and Cryoprecipitate: Observational Cross-Sectional Study. Asian Hematol Res J (2019) 2:1–7.
- Rock G, Shumak KH, Sutton DM, Buskard NA, Nair RC. Cryosupernatant as Replacement Fluid for Plasma Exchange in Thrombotic Thrombocytopenic Purpura. Members of the Canadian Apheresis Group. Br J Haematol (1996) 94:383–6. 10.1046/j.1365-2141.1996.d01-1800.x
- Van Damme KFA, Tavernier S, Van Roy N, De Leeuw E, Declercq J, Bosteels C, et al. . Case Report: Convalescent Plasma, a Targeted Therapy for Patients With CVID and Severe COVID-19. Front Immunol (2020) 11:596761. 10.3389/fimmu.2020.596761
- Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, et al. . Cell Entry Mechanisms of SARS-CoV-2. Proc Natl Acad Sci USA (2020) 117:11727–34. 10.1073/pnas.2003138117
- Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell (2020) 181:271–80.e8. 10.1016/j.cell.2020.02.052
Source: PubMed